论文部分内容阅读
目的:探讨脑蛋白水解物联合九味镇心颗粒治疗小儿多动症的临床疗效,为临床或科研提供科学依据。方法:选取76例小儿多动症患者为研究对象,随机分为对照组和研究组。其中对照组患者36例给予脑蛋白水解物治疗,研究组患者40例给予脑蛋白水解物联合九味镇心颗粒治疗;治疗1个月后复查,观察并记录两组患者治疗前后Conner简明症状量表评分表(ASQ)的变化及患者不良反应和临床疗效。结果:治疗前两组患者ASQ比较差异不显著(P>0.05),经治疗后,研究组患者ASQ明显低于对照组,差异具有统计学意义(P<0.05);对照组和研究组不良反应率分别为8.3%、7.5%,两组比较差异无统计学意义(P>0.05);对照组和研究组总有效率分别为86.1%、97.5%,两组比较差异具有统计学意义(P<0.05)。结论:采用脑蛋白水解物联合九味镇心颗粒治疗小儿多动症,安全有效,可明显改善患者的症状,值得临床推广应用。
Objective: To investigate the clinical efficacy of brain protein hydrolyzate combined with Jiuwei Zhenxin Granule in the treatment of children with ADHD, and provide a scientific basis for clinical or scientific research. Methods: A total of 76 ADHD patients were selected as study subjects and randomly divided into control group and study group. 36 patients in the control group were treated with brain hydrolyzate, and 40 patients in the study group were treated with brain protein hydrolyzate combined with JI Wei Zhenxin Granule. After one month’s treatment, the patients were reviewed and the Conner’s Concordant Symptoms Table score table (ASQ) changes and patient adverse reactions and clinical efficacy. Results: There was no significant difference in ASQ between the two groups before treatment (P> 0.05). After treatment, the ASQ in the study group was significantly lower than that in the control group (P <0.05). The adverse reactions of the control group and the study group (P> 0.05). The total effective rates of the control group and the study group were 86.1% and 97.5%, respectively, with significant difference between the two groups (P < 0.05). Conclusion: It is safe and effective to treat children ADHD with brain protein hydrolyzate combined with JI Wei Zhenxin Granule, which can significantly improve the symptoms of patients and is worthy of clinical application.